Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.

BACKGROUND: Staphylococcus aureus bacteraemia is a common and serious infection, with an associated mortality of ~25%. Once in the blood, S. aureus can disseminate to infect almost any organ, but bones, joints and heart valves are most frequently affected. Despite the infection's severity, the...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Thwaites, G, Auckland, C, Barlow, G, Cunningham, R, Davies, G, Edgeworth, J, Greig, J, Hopkins, S, Jeyaratnam, D, Jenkins, N, Llewelyn, M, Meisner, S, Nsutebu, E, Planche, T, Read, R, Scarborough, M, Soares, M, Tilley, R, Török, M, Williams, J, Wilson, P, Wyllie, S, Walker, A
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: 2012
_version_ 1826272459711578112
author Thwaites, G
Auckland, C
Barlow, G
Cunningham, R
Davies, G
Edgeworth, J
Greig, J
Hopkins, S
Jeyaratnam, D
Jenkins, N
Llewelyn, M
Meisner, S
Nsutebu, E
Planche, T
Read, R
Scarborough, M
Soares, M
Tilley, R
Török, M
Williams, J
Wilson, P
Wyllie, S
Walker, A
author_facet Thwaites, G
Auckland, C
Barlow, G
Cunningham, R
Davies, G
Edgeworth, J
Greig, J
Hopkins, S
Jeyaratnam, D
Jenkins, N
Llewelyn, M
Meisner, S
Nsutebu, E
Planche, T
Read, R
Scarborough, M
Soares, M
Tilley, R
Török, M
Williams, J
Wilson, P
Wyllie, S
Walker, A
author_sort Thwaites, G
collection OXFORD
description BACKGROUND: Staphylococcus aureus bacteraemia is a common and serious infection, with an associated mortality of ~25%. Once in the blood, S. aureus can disseminate to infect almost any organ, but bones, joints and heart valves are most frequently affected. Despite the infection's severity, the evidence guiding optimal antibiotic therapy is weak: fewer than 1,500 patients have been included in 16 randomised controlled trials investigating S. aureus bacteraemia treatment. It is uncertain which antibiotics are most effective, their route of administration and duration, and whether antibiotic combinations are better than single agents. We hypothesise that adjunctive rifampicin, given in combination with a standard first-line antibiotic, will enhance killing of S. aureus early in the treatment course, sterilise infected foci and blood faster, and thereby reduce the risk of dissemination, metastatic infection and death. Our aim is to determine whether adjunctive rifampicin reduces all-cause mortality within 14 days and bacteriological failure or death within 12 weeks from randomisation. METHODS: We will perform a parallel group, randomised (1:1), blinded, placebo-controlled trial in NHS hospitals across the UK. Adults (≥ 18 years) with S. aureus (meticillin-susceptible or resistant) grown from at least one blood culture who have received ≤ 96 h of active antibiotic therapy for the current infection and do not have contraindications to the use of rifampicin will be eligible for inclusion. Participants will be randomised to adjunctive rifampicin (600-900 mg/day; orally or intravenously) or placebo for the first 14 days of therapy in combination with standard single-agent antibiotic therapy. The co-primary outcome measures will be all-cause mortality up to 14 days from randomisation and bacteriological failure/death (all-cause) up to 12 weeks from randomisation. 940 patients will be recruited, providing >80% power to detect 45% and 30% reductions in the two co-primary endpoints of death by 14 days and bacteriological failure/death by 12 weeks respectively. DISCUSSION: This pragmatic trial addresses the long-standing hypothesis that adjunctive rifampicin improves outcome from S. aureus bacteraemia through enhanced early bacterial killing. If proven correct, it will provide a paradigm through which further improvements in outcome from S. aureus bacteraemia can be explored.
first_indexed 2024-03-06T22:12:55Z
format Journal article
id oxford-uuid:526ba10d-e83a-4beb-b192-d6acb7b9c4bd
institution University of Oxford
language English
last_indexed 2024-03-06T22:12:55Z
publishDate 2012
record_format dspace
spelling oxford-uuid:526ba10d-e83a-4beb-b192-d6acb7b9c4bd2022-03-26T16:25:32ZAdjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:526ba10d-e83a-4beb-b192-d6acb7b9c4bdEnglishSymplectic Elements at Oxford2012Thwaites, GAuckland, CBarlow, GCunningham, RDavies, GEdgeworth, JGreig, JHopkins, SJeyaratnam, DJenkins, NLlewelyn, MMeisner, SNsutebu, EPlanche, TRead, RScarborough, MSoares, MTilley, RTörök, MWilliams, JWilson, PWyllie, SWalker, A BACKGROUND: Staphylococcus aureus bacteraemia is a common and serious infection, with an associated mortality of ~25%. Once in the blood, S. aureus can disseminate to infect almost any organ, but bones, joints and heart valves are most frequently affected. Despite the infection's severity, the evidence guiding optimal antibiotic therapy is weak: fewer than 1,500 patients have been included in 16 randomised controlled trials investigating S. aureus bacteraemia treatment. It is uncertain which antibiotics are most effective, their route of administration and duration, and whether antibiotic combinations are better than single agents. We hypothesise that adjunctive rifampicin, given in combination with a standard first-line antibiotic, will enhance killing of S. aureus early in the treatment course, sterilise infected foci and blood faster, and thereby reduce the risk of dissemination, metastatic infection and death. Our aim is to determine whether adjunctive rifampicin reduces all-cause mortality within 14 days and bacteriological failure or death within 12 weeks from randomisation. METHODS: We will perform a parallel group, randomised (1:1), blinded, placebo-controlled trial in NHS hospitals across the UK. Adults (≥ 18 years) with S. aureus (meticillin-susceptible or resistant) grown from at least one blood culture who have received ≤ 96 h of active antibiotic therapy for the current infection and do not have contraindications to the use of rifampicin will be eligible for inclusion. Participants will be randomised to adjunctive rifampicin (600-900 mg/day; orally or intravenously) or placebo for the first 14 days of therapy in combination with standard single-agent antibiotic therapy. The co-primary outcome measures will be all-cause mortality up to 14 days from randomisation and bacteriological failure/death (all-cause) up to 12 weeks from randomisation. 940 patients will be recruited, providing >80% power to detect 45% and 30% reductions in the two co-primary endpoints of death by 14 days and bacteriological failure/death by 12 weeks respectively. DISCUSSION: This pragmatic trial addresses the long-standing hypothesis that adjunctive rifampicin improves outcome from S. aureus bacteraemia through enhanced early bacterial killing. If proven correct, it will provide a paradigm through which further improvements in outcome from S. aureus bacteraemia can be explored.
spellingShingle Thwaites, G
Auckland, C
Barlow, G
Cunningham, R
Davies, G
Edgeworth, J
Greig, J
Hopkins, S
Jeyaratnam, D
Jenkins, N
Llewelyn, M
Meisner, S
Nsutebu, E
Planche, T
Read, R
Scarborough, M
Soares, M
Tilley, R
Török, M
Williams, J
Wilson, P
Wyllie, S
Walker, A
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
title Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
title_full Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
title_fullStr Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
title_full_unstemmed Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
title_short Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
title_sort adjunctive rifampicin to reduce early mortality from staphylococcus aureus bacteraemia arrest study protocol for a randomised controlled trial
work_keys_str_mv AT thwaitesg adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT aucklandc adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT barlowg adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT cunninghamr adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT daviesg adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT edgeworthj adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT greigj adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT hopkinss adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT jeyaratnamd adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT jenkinsn adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT llewelynm adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT meisners adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT nsutebue adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT planchet adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT readr adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT scarboroughm adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT soaresm adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT tilleyr adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT torokm adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT williamsj adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT wilsonp adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT wyllies adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
AT walkera adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial